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Abstract. The Ebola virus disease is a severe viral haemorrhagic fever syn-
drome caused by Ebola virus. This disease is transmitted by direct contact with
the body fluids of an infected person and objects contaminated with virus or
infected animals, with a death rate close to 90% in humans. Recently, some
mathematical models have been presented to analyse the spread of the 2014
Ebola outbreak in West Africa. In this paper, we introduce vaccination of the
susceptible population with the aim of controlling the spread of the disease and
analyse two optimal control problems related with the transmission of Ebola
disease with vaccination. Firstly, we consider the case where the total number
of available vaccines in a fixed period of time is limited. Secondly, we analyse
the situation where there is a limited supply of vaccines at each instant of time
for a fixed interval of time. The optimal control problems have been solved
analytically. Finally, we have performed a number of numerical simulations in
order to compare the models with vaccination and the model without vacci-
nation, which has recently been shown to fit the real data. Three vaccination
scenarios have been considered for our numerical simulations, namely: unlim-
ited supply of vaccines; limited total number of vaccines; and limited supply
of vaccines at each instant of time.
1. Introduction. Ebola is a lethal virus for humans that is currently under strong
research due to the recent outbreak in West Africa and its socioeconomic impact
(see, e.g., [5, 17, 18, 21, 24, 25, 30, 34, 37] and references therein). World Health
Organization (WHO) has declared Ebola virus disease epidemic as a public health
emergency of international concern with severe global economic burden. At fatal
Ebola infection stage, patients usually die before the antibody response. Mainly
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after the 2014 Ebola outbreak in West Africa, some attempts to obtain a vaccine
for Ebola disease have been realized. According to the WHO, results in July 2015
from an interim analysis of the Guinea Phase III efficacy vaccine trial show that
VSV-EBOV (Merck, Sharp & Dohme) is highly effective against Ebola [2].
Since 2014, different mathematical models to analyze the spread of the 2014
Ebola outbreak have been presented (see, e.g., [3, 4, 19, 32, 33] and references
therein). In these models the populations under study are divided into compart-
ments, and the rates of transfer between compartments are expressed mathemat-
ically as derivatives with respect to time of the size of the compartments. In a
recent work [4], a system of eight nonlinear (fractional) differential equations for
a population divided into eight mutually exclusive groups was considered: suscep-
tible, exposed, infected, hospitalized, asymptomatic but still infectious, dead but
not buried, died, and completely recovered. By comparing the numerical results of
this mathematical model and the real data provided by WHO, the difference in the
period of 438 days analyzed is about 7 cases per day. Note that in the day 438 after
the beginning of the outbreak, the number of confirmed cases is 15018.
There exist different models for the spreading of Ebola, beginning with the sim-
plest SIR and SEIR models [2, 9, 10] and later more complex but also more re-
alistic models have been considered [4, 24, 29]. In [25], a stochastic discrete-time
Susceptible-Exposed-Infectious-Recovered (SEIR) model for infectious diseases is
developed with the aim of estimating parameters from daily incidence and mortal-
ity time series for an outbreak of Ebola in the Democratic Republic of Congo in
1995. In [24], the authors use data from two epidemics (in Democratic Republic of
Congo in 1995 and in Uganda in 2000) and built a SEIHFR (Susceptible-Exposed-
Infectious-Hospitalized-F(dead but not yet buried)-Removed) mathematical model
for the spread of Ebola haemorrhagic fever epidemics taking into account transmis-
sion in different epidemiological settings (in the community, in the hospital, during
burial ceremonies). In [5], the authors propose a SIRD (Susceptible-Infectious-
Recovered-Dead) mathematical model using classical and beta derivatives. In this
model, the class of susceptible individuals does not consider new born or immigra-
tion. The study shows that, for small portion of infected individuals, the whole
country could die out in a very short period of time in case there is no good pre-
vention. In [3], a fractional order SEIR Ebola epidemic model is proposed and the
authors show that the model gives a good approximation to real data published by
WHO, starting from March 27th, 2014.
Optimal control is a mathematical theory that emerged after the Second World
War with the formulation of the celebrated Pontryagin maximum principle, re-
sponding to practical needs of engineering, particularly in the field of aeronautics
and flight dynamics [31]. In the last decade, optimal control has been largely ap-
plied to biomedicine, namely to models of cancer chemotherapy (see, e.g., [23]), and
recently to epidemiological models [15, 26, 36].
In [32], the authors present a comparison between SIR and SEIR mathematical
models used in the description of the Ebola virus propagation. They applied op-
timal control techniques in order to understand how the spread of the virus may
be controlled, e.g., through education campaigns, immunization or isolation. In [1],
the authors introduce a deterministic SEIR type model with additional hospital-
ization, quarantine and vaccination components in order to understand the disease
dynamics. Optimal control strategies, both in the case of hospitalization (with and
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without quarantine) and vaccination, are used to predict the possible future out-
come in terms of resource utilization for disease control and the effectiveness of
vaccination on sick populations. Both in [1] and [32], the authors study optimal
control problems with L2 cost functionals without any state or control constraints.
Here, we modify the model analyzed in [4] in order to consider optimal control
problems with vaccination constraints. More precisely, we introduce an extra vari-
able for the number of vaccines used, and we compare the hypothetical results if
the vaccine were available at the beginning of the outbreak with the results of the
model without vaccines. Firstly, we consider an optimal control problem with an
end-point state constraint, that is, the total number of available vaccines, in a fixed
period of time, is limited. Secondly, we analyze an optimal control problem with a
mixed state constraint, in which there is a limited supply of vaccines at each instant
of time for a fixed interval of time. Both optimal control problems have been an-
alytically solved. Moreover, we have performed a number of numerical simulations
in three different scenarios: unlimited supply of vaccines; limited total number of
vaccines to be used; and limited supply of vaccines at each instant of time. From
the results obtained in the first two cases, when there is no limit in the supply of
vaccines or when the total number of vaccines used is limited, the optimal vaccina-
tion strategy implies a vaccination of 100% of the susceptible population in a very
short period of time (smaller than one day). In practice, this is a very difficult task
because limitations in the number of vaccines and also in the number of humani-
tarian and medical teams in the affected regions are common. In this direction, the
third analyzed case is extremely important since we consider a limited supply of
vaccines at each instant of time.
The paper is organized as follows. In Section 2, we recall a mathematical model
for Ebola virus. In Section 3, the introduction of effective vaccination for Ebola
virus is modeled. An optimal control problem with an end-point state constraint is
formulated and solved analytically in Section 4, which models the case where the
total number of available vaccines in a fixed period of time is limited. In Section 5,
the limited supply of vaccines at each instant of time for a fixed interval of time
is mathematically translated into an optimal control problem with a mixed state
control constraint. A closed form of the unique optimal control is given. In Section 6,
we solve numerically the optimal control problems proposed in Sections 4 and 5.
Finally, we end with Section 7 of discussion of the results.
2. Initial mathematical model for Ebola. The total population N under study
is subdivided into eight mutually exclusive groups: susceptible (S), exposed (E),
infected (I), hospitalized (H), asymptomatic but still infectious (R), dead but not
buried (D), buried (B), and completely recovered (C). This model is adapted from
[20] and analyzed in [4], where the birth and death rate are assumed to be equal
and are denoted by µ, and the contact rate of susceptible individuals with infective,
dead, hospitalized and asymptomatic individuals are denoted by βi, βd, βh and βr,
respectively. Exposed individuals become infectious at a rate σ. The per capita
rate of progression of individuals from the infectious class to the asymptomatic and
hospitalized classes are denoted by γ1 and τ , respectively. Individuals in the dead
class progress to the buried class at a rate δ1. Hospitalized individuals progress
to the buried class and to the asymptomatic class at rates δ2 and γ2, respectively.
Asymptomatic individuals become completely recovered at a rate γ3. Infectious
individuals progress to the dead class at a fatality rate . Dead and buried bodies
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are incinerated at a rate ξ. We assume that the total population, N = S +E + I +
R +H +D + B + C, is constant, that is, the birth and death rates, both denoted
by µ, are equal to the incineration rate ξ. The model is mathematically described
by the following system of eight nonlinear ordinary differential equations:

dS
dt
= µN − βi
N
SI − βh
N
SH − βd
N
SD − βr
N
SR− µS,
dE
dt
=
βi
N
SI +
βh
N
SH +
βd
N
SD +
βr
N
SR− σE − µE,
dI
dt
= σE − (γ1 + + τ + µ)I,
dR
dt
= γ1I + γ2H − (γ3 + µ)R,
dD
dt
= I − δ1D − ξD,
dH
dt
= τI − (γ2 + δ2 + µ)H,
dB
dt
= δ1D + δ2H − ξB
dC
dt
= γ3R− µC.
(1)
In Fig. 1, we give a flowchart presentation of model (1). In this flowchart, we
identify the compartmental classes as well as the parameters appearing in the model.
Moreover, the values of the parameters are given in Table 1.
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Figure 1. Flowchart presentation of the compartmental model
(1) for Ebola.
The basic reproduction number (that is, the number of cases one case generates
on average over the course of its infectious period, in an otherwise uninfected pop-
ulation) of model (1) can be computed using the associated next-generation matrix
method [13]. It is obtained as the spectral radius of the following matrix, known as
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the next-generation-matrix:
FV −1 =

A11 A12 A13 A14 A15
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
 ,
where
A11 =
a3βiσa1a4 + a3βrσ (a4γ1 + τγ2) + βdσa1a4 + a3βhτσa1
a1a2a3a4a5
,
A12 =
βr
a1
+
βr(a4γ1 + τγ2)
a1a2a3
+
βd
a2a3
+
βhτ
a2a4
,
A13 =
βr
a1
, A14 =
βd
a3
, A15 =
βrγ2
a1a4
+
βh
a4
with
a1 = γ2+δ2+µ, a2 = γ3+µ, a3 = δ1+ξ, a4 = σ+µ, and a5 = γ1++τ+µ.
Therefore, the basic reproduction number R0 is given by
R0 =
σ
a1a2a3a4a5
[
a3
(
βi(γ3a1 + µ(γ2 + δ2) + µ
2) + βr(γ1a1 + γ2τ) + βhτa2
)
+βd
(
(γ3a1 + µ(γ2 + δ2)) + µ
2
)]
.
As it is well-known, if the basic reproduction number R0 < 1, then the infection
will stop in the long run; but if R0 > 1, then the infection will spread in population.
In this section, we have recalled a model for describing the Ebola virus transmis-
sion. Now we want to address the question about how to introduce vaccination as
a prevention measure. This is analyzed in the next section.
3. Mathematical model for Ebola with vaccination. We now introduce vac-
cination of the susceptible population with the aim of controlling the spread of the
disease. We assume that the vaccine is effective so that all vaccinated susceptible
individuals become completely recovered (see, e.g., [6, 27] for vaccination in a SEIR
model that corresponds to a system of four nonlinear ordinary differential equa-
tions). Let us introduce in model (1) a control function u(t), which represents the
percentage of susceptible individuals being vaccinated at each instant of time t with
t ∈ [0, tf ]. Unfortunately, in many situations, the number of available vaccines does
not fulfill the necessities in order to eradicate the disease. In this paper, we consider
limitations on the total number of vaccines during a fixed interval of time [0, tf ] and
on the number of available vaccines at each instant of time t with t ∈ [0, tf ]. In
order to translate this real situation mathematically, we introduce an extra variable
W that denotes the number of vaccines used:
dW
dt
(t) = u(t)S(t), subject to the initial condition W (0) = 0.
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Symbol Description Value
σ per capita rate at which exposed individuals become infectious 1/11.4
µ death rate 14/1000
βi contact rate of infective and susceptible individuals 0.14
βd contact rate of infective and dead individuals 0.40
βh contact rate of infective and hospitalized individuals 0.29
βr contact rate of infective and asymptomatic individuals 0.185
γ1 per capita rate of progression of individuals from the infectious class
to the asymptomatic class 1/10
 fatality rate 1/9.6
δ1 per capita rate of progression of individuals from the dead class
to the buried class 1/2
δ2 per capita rate of progression of individuals from the hospitalized class
to the buried class 1/4.6
γ2 per capita rate of progression of individuals from the hospitalized class
to the asymptomatic class 1/5
τ per capita rate of progression of individuals from the infectious class
to the hospitalized class 1/5
γ3 per capita rate of progression of individuals from the asymptomatic class
to the completely recovered class 1/30
ξ incineration rate 14/1000
Table 1. Parameter values for model (1), corresponding to a basic re-
production number R0 = 2.287. The values of the parameters come from
[7, 14, 22, 24, 28, 34, 35].
Hence, the model with vaccination is given by the following system of nine nonlinear
ordinary differential equations:
dS
dt
(t) = µN − βi
N
S(t)I(t)− βh
N
S(t)H(t)− βd
N
S(t)D(t)
−βr
N
S(t)R(t)− µS(t)− S(t)u(t),
dE
dt
(t) =
βi
N
S(t)I(t) +
βh
N
S(t)H(t) +
βd
N
S(t)D(t)
+
βr
N
S(t)R(t)− σE(t)− µE(t),
dI
dt
(t) = σE(t)− (γ1 + + τ + µ)I(t),
dR
dt
(t) = γ1I(t) + γ2H(t)− (γ3 + µ)R(t),
dD
dt
(t) = I(t)− (δ1 + ξ)D(t),
dH
dt
(t) = τI(t)− (γ2 + δ2 + µ)H(t),
dB
dt
(t) = δ1D(t) + δ2H(t)− ξB(t),
dC
dt
(t) = γ3R(t)− µC(t) + S(t)u(t),
dW
dt
(t) = S(t)u(t).
(2)
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In model (2), the vaccination parameter is fixed. In the next section, we address
the question of how to choose this parameter in an optimal way along time.
4. Optimal control with an end-point state constraint. We start by consid-
ering the case where the total number of available vaccines, in a fixed period of
time, is limited. We formulate and solve analytically such optimal control problem
with end-point state constraint, which will be then solved numerically in Section 6.
We consider the model with vaccination (2) and formulate the optimal control
problem with the aim to determine the vaccination strategy u over a fixed interval
of time [0, tf ] that minimizes the cost functional
J(u) =
∫ tf
0
[
w1I(t) + w2u
2(t)
]
dt, (3)
where the constants w1 and w2 represent the weights associated with the number
of infected individuals and on the cost associated with the vaccination program,
respectively. We assume that the control function u takes values between 0 and 1.
When u(t) = 0, no susceptible individual is vaccinated at time t; if u(t) = 1, then
all susceptible individuals are vaccinated at t. Let ϑ denote the total amount of
available vaccines in a fixed period of time [0, tf ]. This constraint is represented by
W (tf ) ≤ ϑ. (4)
Let
x(t) = (x1(t), . . . , x9(t)) = (S(t), E(t), I(t), R(t), D(t), H(t), B(t), C(t),W (t)) ∈ R9.
The optimal control problem consists to find the optimal trajectory x˜ associated
with the optimal control u˜, satisfying the control system (2), the initial conditions
x(0) = (18000, 0, 15, 0, 0, 0, 0, 0, 0) (5)
(see [4]), the constraint (4), and where the control u˜ ∈ Ω minimizes the objective
functional (3) with
Ω =
{
u(·) ∈ L∞(0, tf ) | 0 ≤ u(t) ≤ 1
}
. (6)
The existence of an optimal control u˜ and associated optimal trajectory x˜ comes
from the convexity of the integrand of the cost function (3) with respect to the
control u and the Lipschitz property of the state system with respect to state
variables x (see, e.g., [8, 16] for existence results of optimal solutions). According
to the Pontryagin Maximum Principle [31], if u˜ ∈ Ω is optimal for the problem
(2), (3) with initial conditions (5) and fixed final time tf , then there exists λ ∈
AC([0, tf ];R9), λ(t) = (λ1(t), . . . , λ9(t)), called the adjoint vector, such that
x˙ =
∂H1
∂λ
and λ˙ = −∂H1
∂x
,
where the Hamiltonian H1 is defined by
H1(x, u, λ) = w1x3 + w2u2(t) + λ (f(x) +Ax+Bxu)
with
f = (f1 f2 0 0 0 0 0 0 0) ,
f1 = µN − βi
N
S(t)I(t)− βh
N
S(t)H(t)− βd
N
S(t)D(t)− βr
N
S(t)R(t),
f2 =
βi
N
S(t)I(t) +
βh
N
S(t)H(t) +
βd
N
S(t)D(t) +
βr
N
S(t)R(t),
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A =

−µ 0 0 0 0 0 0 0
0 −σ − µ 0 0 0 0 0 0
0 σ Λ 0 0 0 0 0
0 0 γ1 −(γ3 + µ) 0 γ2 0 0
0 0  0 −(δ1 + ξ) 0 0 0
0 0 τ 0 0 −(γ2 + δ2 + µ) 0 0
0 0 0 0 δ1 δ2 −ξ 0
0 0 0 γ3 0 0 0 −µ
0 0 0 0 0 0 0 0

with Λ = −(γ1 + + τ + µ), and
B = (b Z) ,
where b = (−1 0 0 0 0 0 0 1 1)T and Z = 0 with 0 the 8 × 9 null matrix. The mini-
mization condition
H1
(
x˜(t), u˜(t), λ˜(t)
)
= min
u∈Ω
H1
(
x˜(t), u, λ˜(t)
)
(7)
holds almost everywhere on [0, tf ]. Moreover, transversality conditions λi(tf ) = 0,
i = 1, . . . , 8, hold. Solving the minimality condition (7) on the interior of the set of
admissible controls Ω gives
u˜(t) = −1
2
(
−λ˜1(t) + λ˜8(t) + λ˜9(t)
)
x˜1(t)
ω2
,
where the adjoint functions satisfy
˙˜
λ1 = −λ˜1
(
−βi
N
x˜3 − βh
N
x˜6 − βd
N
x˜5 − βr
N
x˜4 − µ− u˜
)
−λ˜2
(
βi
N
x˜3 +
βh
N
x˜6 +
βd
N
x˜5 +
βr
N
x˜4
)
− λ˜8u˜− λ˜9u˜,
˙˜
λ2 = −λ˜2 (−σ − µ)− λ˜3 σ,
˙˜
λ3 = −ω1 + λ˜1 βi
N
x˜1 − λ˜2 βi
N
x˜1 − λ˜3 (−γ1 − − τ − µ)− λ˜4γ1 − λ˜5− λ˜6τ,
˙˜
λ4 = λ˜1
βr
N
x˜1 − λ˜2 βr
N
x˜1 − λ˜4 (−γ3 − µ)− λ˜8γ3,
˙˜
λ5 = λ˜1
βd
N
x˜1 − λ˜2 βd
N
x˜1 − λ˜5 (−δ1 − ξ)− λ˜7δ1,
˙˜
λ6 = λ˜1
βh
N
x˜1 − λ˜2 βh
N
x˜1 − λ˜4γ2 − λ˜6 (−γ2 − δ2 − µ)− λ˜7δ2,
˙˜
λ7 = λ˜7ξ,
˙˜
λ8 = λ˜8µ,
˙˜
λ9 = 0.
(8)
Since W has initial and terminal conditions, the adjoint function λ9, associated with
the state variable W , has no transversality condition. From (8), λ˜9 ≡ k, where the
constant k must be such that the end point conditions W (0) = 0 and W (tf ) = ϑ are
satisfied. As the optimal control u˜ can take values on the boundary of the control
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set [0, 1], the optimal control u˜ must satisfy
u˜(t) = min
1,max
0, 12
(
λ˜1(t)− λ˜8(t)− λ˜9(t)
)
x˜1(t)
ω2

 . (9)
The optimal control u˜ given by (9) is unique due to the boundedness of the state
and adjoint functions and the Lipschitz property of systems (2) and (8).
We would like to note that if we consider the optimal control problem without any
restriction on the number of available vaccines, that is, to find the optimal solution
(x˜, u˜), with u˜ ∈ Ω, which minimizes the cost functional (3) subject to the control
system (2), initial conditions (5), and free final conditions (x1(tf ), . . . , x9(tf )), then
the adjoint functions (λ1, . . . , λ9) must satisfy transversality conditions λi(tf ) = 0,
i = 1, . . . , 9, and, since λ˜9 = 0, the optimal control is given by
u˜(t) = min
1,max
0, 12
(
λ˜1(t)− λ˜8(t)
)
x˜1(t)
ω2

 .
In a concrete situation, the number of available vaccines is always limited. There-
fore, it is also important to study the optimal control problem with such kind of
constraints. This is done in Section 5. Both problems, with and without constraints,
are numerically solved in Section 6.
5. Optimal control with a mixed state control constraint. A particularly
challenging situation in vaccination programs happens when there is a limited sup-
ply of vaccines at each instant of time for a fixed interval of time [0, tf ]. In order to
study this health public problem, from the optimal point of view, we formulate an
optimal control problem with a mixed state control constraint (see, e.g., [6]). The
cost functional (3) remains (3), the one considered in previous section, as well as
the set of admissible controls Ω (6). The end point state constraint (4) is replaced
by the following mixed state control constraint:
S(t)u(t) ≤ ϑ , ϑ ≥ 0 , for almost all t ∈ [0, tf ],
which should be satisfied at almost every instant of time during the whole vaccina-
tion program. Analogously to [6], we observe that in our optimal control problem
the differential equation
dW
dt
(t) = S(t)u(t)
does not appear neither in the cost and in any other differential equation, nor in
the mixed state control constraint. Thus, in this section, the control system does
not include the last equation and x is used to denote
x(t) = (x1(t), . . . , x8(t)) = (S(t), E(t), I(t), R(t), D(t), H(t), B(t), C(t)) ∈ R8.
Let us consider the initial conditions (5). The control system can be rewritten in
the following way:
dx(t)
dt
= f(x(t)) +Ax(t) +Bx(t)u(t),
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with
A =

−µ 0 0 0 0 0 0 0
0 −σ − µ 0 0 0 0 0 0
0 σ Λ 0 0 0 0 0
0 0 γ1 −(γ3 + µ) 0 γ2 0 0
0 0  0 −(δ1 + ξ) 0 0 0
0 0 τ 0 0 −(γ2 + δ2 + µ) 0 0
0 0 0 0 δ1 δ2 −ξ 0
0 0 0 γ3 0 0 0 −µ

,
Λ = −(γ1 + + τ + µ),
B = (b Z) ,
where b = (−1 0 0 0 0 0 0 1)T and Z = 0 with 0 the 7× 8 null matrix, and
f = (f1 f2 0 0 0 0 0 0) ,
with
f1 = µN − βi
N
S(t)I(t)− βh
N
S(t)H(t)− βd
N
S(t)D(t)− βr
N
S(t)R(t)
and
f2 =
βi
N
S(t)I(t) +
βh
N
S(t)H(t) +
βd
N
S(t)D(t) +
βr
N
S(t)R(t).
It follows from Theorem 23.11 in [11] that problem (2)–(6) has a solution (see also
[6]). Let (x˜, u˜) denote such solution. To determine it, we apply the Pontryagin
Maximum Principle (see, e.g., Theorem 7.1 in [12]): there exists multipliers λ0 ≤ 0,
λ ∈ AC([0, tf ];R8), and ψ ∈ L1([0, tf ];R), such that
• min{|λ(t)| : t ∈ [0, tf ]} > λ0 (nontriviality condition);
• dλ(t)dt = −∂H2∂x (x˜(t), u˜(t), λ0, λ(t), ψ(t)) (adjoint system);
• λ(t)Bx˜(t) + ψ(t)x˜1(t) + λ0w2u˜2(t) ∈ N[0,1](u˜(t)) a.e. and
H2(x˜(t), u˜(t), λ0, λ(t), ψ(t)) ≤ H2(x˜(t), v, λ0, λ(t), ψ(t)), ∀v ∈ [0, 1] : x˜1(t)v ≤ ϑ
(minimality condition);
• ψ(t)(x˜1(t)u˜(t)− ϑ) = 0 and ψ(t) ≤ 0 a.e.;
• λ(tf ) = (0, . . . , 0) (transversality conditions);
where the Hamiltonian H2 for problem (2)–(6) is defined by
H2(x, u, λ0, λ, ψ) = λ0
(
w1x3 + w2u
2
)
+ λ (f(x) +Ax+Bxu) + ψ(Su− ϑ),
and N[0,1](u˜(t)) stands for the normal cone from convex analysis to [0, 1] at the
optimal control u˜(t) (see, e.g., [11]). The optimal solution (x˜, u˜) is normal (see [6]
for details), so we can choose λ0 = 1. Analogously to previous section, we obtain a
closed form of the unique optimal control u˜:
u˜(t) = min
1,max
0, 12
(
λ˜1(t)− λ˜8(t)− ψ(t)
)
x˜1(t)
ω2

 .
The theoretical results obtained in Sections 4 and 5 are illustrated numerically
in the next section.
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6. Numerical simulations. We start the numerical simulations by considering
an intervention of 90 days, initial conditions given in (5), and the evolution of
cumulative confirmed cases based on the data from the World Health Organization
(WHO), following all the reports of the disease in the three main affected countries
of Western Africa of the 2014 Ebola outbreak, namely, Liberia, Guinea and Sierra
Leone. The model (1) with the parameter values from Table 1 fits the real data
from WHO, see Fig. 2a. We would like to emphasize that we are just considering
the initial period of spreading of the disease, in which the vaccination should be
introduced. Looking to a longer period of time (as considered in [4]), then the model
fits quite well the real data: in [4, Figure 2] the `2 norm of the difference between
the real data and the prediction is 3181, which gives an error of less than 7.3 cases
per day, as compared with about 15,000 cases at the end of the outbreak.
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(a) Real data and solution of (1)
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Figure 2. (a) Cumulative confirmed cases: in dashed circle line
the real data from WHO and in continuous line the values of I(t)+
R(t) + D(t) + H(t) + B(t) + C(t) − µ(N − S(t) − E(t)) from (1)
with the parameter values from Table 1. (b) Cumulative confirmed
cases given in (2), when available an unlimited supply of vaccines,
also with the parameter values from Table 1.
Assuming that, in the near future, an effective vaccine against the Ebola virus
will be available, as expected by WHO by the end of 2015, we study three different
scenarios, which illustrate limitations on the number of vaccines available and on
the capacity of administration of the vaccines by the health care services and hu-
manitarian teams working in the affected countries. The three vaccination scenarios
are the following: unlimited supply of vaccines; limited total number of vaccines to
be used; and limited supply of vaccines at each instant of time.
6.1. Unlimited supply of vaccines. Assume w1 = w2 = 1. If we administer
from an unlimited supply of vaccines, then the number of total individuals who
have an active infection I(t)+R(t)+D(t)+H(t)+B(t)−µ(N−S(t)−E(t)−C(t))
during the 90 days is a decreasing function in time, and is equal to 3.56 individuals
at the final time (see Fig. 2b).
If we compare the case where there is no vaccination with the opposite case of
unlimited supply of vaccines, we observe that at the end of 90 days the class of
completely recovered individuals has approximately 86.5 individuals in the case of
no vaccination and 13468 in the case of unlimited vaccination, which represents 74.82
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per cent of the total population (see Fig. 3–4). If vaccines are available, then the
number of individuals that develop active disease is less than one at the end of 7.5
days and less that 0.1 at the end of 32.4 days. In the case of no vaccination, the class
of active infected individuals has 61.7 individuals at the end of 90 days (see Fig. 3). If
no vaccination is provided, then the number of deaths, hospitalizations and burials
increases from 1.2 to 262.6, when compared to the case of unlimited supply of
vaccines (see Fig. 4). The optimal vaccination policy suggested by the solution
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Figure 3. Individuals S(t), E(t), I(t) and R(t). In dashed line,
the case of vaccination without limit on the supply of vaccines; in
continuous line, the case with no vaccination with the parameter
values from Table 1.
of the optimal problem, implies a vaccination of 100 per cent of the susceptible
population for approximately 1.62 days followed by a fast reduction of the fraction
of susceptible population that is vaccinated. This is based on the fact that the
vaccine is effective and once all the susceptible population is vaccinated in a short
period of time, then the number of susceptible individuals immediately decreases,
since they are transferred to the class of completely recovered individuals, as well as
the need of vaccination (see Fig. 5a). The previous results show the importance of
an effective vaccine for Ebola virus and the very good results that can be attained
if the number of available vaccines satisfies the needs of the population.
6.2. Limited total number of vaccines. In Fig. 5b, we observe that at the end
of 90 days, 33786 vaccines were used, if the supply of vaccines is unlimited. In this
section, we consider the case where the total number of vaccines used in the 90 days
period is limited. We consider the case where the total number of vaccines available
is lower or equal than the initial number of susceptible individuals (W (90) ≤ 10000,
W (90) ≤ 11000, W (90) ≤ 13000, W (90) ≤ 15000, W (90) ≤ 16000, W (90) ≤ 18000)
and the case where the total number of vaccines available is bigger than the initial
number of susceptible individuals (W (90) ≤ 20000). We first consider w1 = w2 = 1.
The cumulative confirmed cases (see Fig. 6) increases in time in the case W (90) ≤
EBOLA MODEL AND OPTIMAL CONTROL 13
0 50 100
0
5
10
15
time (days)
D
 
 
Vaccination
No vaccination
0 50 100
0
10
20
30
time (days)
H
 
 
Vaccination
No vaccination
0 50 100
0
100
200
300
time (days)
B
 
 Vaccination
No vaccination
0 50 100
0
0.5
1
1.5
2
x 104
time (days)
C
 
 
Vaccination
No vaccination
Figure 4. Individuals D(t), H(t), B(t) and C(t), with the param-
eter values from Table 1. In dashed line, the case of vaccination
without limit on the supply of vaccines; in continuous line, the case
of no vaccination.
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Figure 5. Optimal control and number of vaccines with the pa-
rameter values from Table 1, when an unlimited supply of vaccines
is available.
10000 and decreases in the case W (90) ≤ 20000, t ∈ [0, 90]. At the end of the 90 days
period, the total number of individuals who got active infection is approximately
76 and 9.5 individuals in the case W (90) ≤ 10000 and W (90) ≤ 20000, respectively.
In the case W (90) ≤ 10000, the optimal control takes the maximum value for less
than one day (approximately 0.72 days) with a cost equal to 322.74, and in the case
W (90) ≤ 20000, the optimal control takes the maximum value for approximately
2.2 days with a cost equal to 72.35. The cost associated to the case W (90) ≤ 20000
is lower than the one in the case W (90) ≤ 10000, although more individuals are
vaccinated, since the number of individuals in the class I is lower. Namely, in the
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Figure 6. (a) Cumulative confirmed cases. (b) Optimal control
for the case of limited total number of vaccines. Dashed line for
W (90) ≤ 10000 and continuous line for W (90) ≤ 20000.
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Figure 7. Individuals S(t), E(t), I(t) and R(t). The dashed line
represents the case where W (90) ≤ 10000 and the continuous line
represents the case where W (90) ≤ 20000.
case W (90) ≤ 10000, the number of individuals with active infection at the end
of 90 days is equal to I(90) = 8.4 and in the case W (90) ≤ 20000 the respective
number is equal to I(90) = 0.67. This means that in the case W (90) ≤ 10000, in
a epidemiological scenario corresponding to a basic reproduction number greater
than one, 10000 vaccines will not be enough to eradicate the disease. Additionally,
if we consider the maximum value for the total number of vaccines used during
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Figure 8. Individuals D(t), H(t), B(t) and C(t). The dashed line
represents the case where W (90) ≤ 10000 and the continuous line
represents the case where W (90) ≤ 20000.
the period of 90 days to be equal to 11000, 13000, 15000, 16000 and 18000, then
we observe that the optimal control u remains more time at the maximum value
1 when the supply of vaccines is bigger, which means that when the total number
of available vaccines is increased there will be resources to vaccinate all susceptible
individuals for a longer period of time, which implies a bigger reduction of the
number of individuals who get infected by the virus (see Fig. 9a and 9b for the
optimal control strategy and respective zoom in the period of vaccination).
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Figure 9. Optimal control u(t) and number of vaccines W (t) for
W (90) ≤ 10000, W (90) ≤ 11000, W (90) ≤ 13000, W (90) ≤ 15000,
W (90) ≤ 16000, W (90) ≤ 18000 and W (90) ≤ 20000.
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Consider now the case where the weight constant associated with the cost of
implementation of the vaccination strategy, designated by the optimal control u,
is bigger than one, for example, consider w1 = 1 and w2 = 50, and w1 = 1 and
w2 = 500. To simplify, consider in both cases W (90) ≤ 10000 and W (90) ≤ 20000.
When we increase the weight constant w2, the maximum value attained by the
optimal control becomes lower than one (see Fig. 10). In the case W (90) ≤ 10000 for
w2 = 50, the optimal control starts with the value u(0) = 0.54 and is a decreasing
function with a cost function 344.3. At the end of approximately 3.7 days, the
control remains equal to zero. For w2 = 500, the optimal control starts with the
value u(0) = 0.16 and is also a decreasing function, with a cost 399.62. At the end
of 13.5 days, it remains equal to zero. The behavior of the optimal state variables
S, E, I, R, D, H, B and C are similar.
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Figure 10. Optimal control u(t) and number of vaccines W (t) for
W (90) ≤ 10000. In dashed line the case w2 = 50 and in continuous
line the case w2 = 500.
6.3. Limited supply of vaccines at each instant of time. From previous re-
sults, we observe that when there is no limit on the supply of vaccines, or when the
total number of used vaccines is limited, the optimal vaccination strategy implies
a vaccination of 100 per cent of the susceptible population in a very short period
of time, sometimes smaller than one day. But we know that in practice this is a
very difficult task, since there are limitations in the number of vaccines available
and also in the number of health care workers or humanitarian teams in the regions
affected by Ebola virus with capacity to vaccinate such a big number of individuals
almost simultaneously. From this point of view, it is important to study the case
where there is a limited supply of vaccines at each instant of time. In this section,
we consider w1 = w2 = 1, a shorter interval of time [0, tf ], with tf = 10, 15, 16,
and we assume that at each instant of time there exist only 1000, 1200 and 900
available vaccines, respectively. From our point of view, these numbers of available
vaccines at each instant of time and the number of days considered, correspond
to possible real scenarios, which are possible to implement in a concrete endemic
region and at the same time characterize lack of human and material resources to
vaccinate the susceptible population in a short period of time. From the numerical
simulations, for such mixed constraints, the number of cumulative confirmed cases
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increases with time (see Figure 11a). The cost associated with the vaccination cam-
paign, associated with the solution of the optimal control problem with the mixed
constraint S(t)u(t) ≤ 1000, t ∈ [0, 10], is equal to 45.8879. Such solution is the
less costly of the three considered, followed by the constraint S(t)u(t) ≤ 1200 for
t ∈ [0, 15] with a cost of 55.079. The most expensive vaccination strategy is the
one associated with the mixed constraint S(t)u(t) ≤ 900, t ∈ [0, 16], with a cost
of 59.109. The strategy associated with the constraint S(t)u(t) ≤ 1000 is the one
where a lowest number of susceptible individuals completely recover through vacci-
nation, with 7540.9 individuals in the class C at the end of 10 days. If we consider
that at each instant of time there are 1200 vaccines available during a period of 15
days, then 12438 completely recover. This is the strategy with more individuals in
the class C. If we consider 16 days, but only 900 vaccines available for each instant
of time, then only 10839 individuals completely recover (see Fig. 11b). For all three
mixed constraint situations, the number of individuals in the classes E, I, R, D,
H and B does not change significantly (therefore, the figures with these classes are
omitted). As the number of available vaccines represent a small percentage of the
susceptible population, in the three cases the optimal vaccination strategies for the
constraints S(t)u(t) ≤ 1200 and S(t)u(t) ≤ 900 suggest that the percentage of the
susceptible population that is vaccinated is always inferior than 18 percent. In the
case of the constraint S(t)u(t) ≤ 1000, this percentage is always inferior to 8 percent
(see Fig. 11c).
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Figure 11. (a) Cumulative confirmed cases, (b) completely recov-
ered, (c) optimal control. In (a), (b) and (c) the following mixed
constraints are considered: S(t)u(t) ≤ 1000 for all t ∈ [0, 10],
S(t)u(t) ≤ 1200 for all t ∈ [0, 15], and S(t)u(t) ≤ 900 for all
t ∈ [0, 16].
7. Discussion. We assume that, in a near future, an effective vaccine against the
Ebola virus will be available. Under this assumption, three different scenarios have
been studied: unlimited supply of vaccines; limited total number of vaccines to be
used; and limited supply of vaccines at each instant of time. We have solved the
optimal control problems analytically and we have performed a number of numerical
simulations in the three aforementioned vaccination scenarios.
Some authors have already considered the optimal control problem with vacci-
nation for Ebola disease, but always with unlimited supply of vaccines [1, 32]. It
turns out that the solution to this mathematical problem is obvious: the solution
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consists to vaccinate all susceptible individuals in the beginning of the outbreak.
This is a very particular case of our work, investigated in Section 6.1 (see Figure 5).
If vaccines are available without any restriction, then one could completely eradi-
cate Ebola in a very short period of time. These results show the importance of an
effective vaccine for Ebola virus and the very good results that can be attained if
the number of available vaccines satisfy the needs of the population. Unfortunately,
such situation is not realistic: in case an effective vaccine for Ebola virus will ap-
pear, there always will be restrictions on the number of available vaccines as well
as constraints on how to inoculate them in a proper way and in a short period of
time; economic problems might also exist.
In our work, for first time in the literature of Ebola, an optimal control problem
with state and control constraints has been considered. Mathematically, it rep-
resents a health public problem of limited total number of vaccines. The results
obtained in Section 6.2 provide useful information on the number of vaccines to be
bought, in order to reduce the number of new infections with minimum cost. For
example, the results between 10000 and 20000 vaccines (in 90 days) are completely
different. With 10000 vaccines, the number of cumulative infected cases continues
to increase, while with 20000 vaccines it is already possible to decrease the new
infections. The optimal solution, in this case, is similar to the case of unlimited
supply of vaccines, that is, it implies a vaccination of 100 per cent of the susceptible
population in a very short period of time. In practice, this is an unrealistic task,
due to the necessary number of vaccines and humanitarian teams in the regions
affected by Ebola. Therefore, we conclude that it is important to study the case
where there is a limited supply of vaccines at each instant of time. This was investi-
gated in Section 6.3. This situation is much richer and the optimal control solution
is not obvious. For a given number of available vaccines at each instant of time, we
have a different solution, which is the optimal rate of susceptible individuals that
should be vaccinated. In this case, the optimal control implies the vaccination of a
small subset of the susceptible population. It remains the ethical problem of how
to choose the individuals to be vaccinated.
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